Prostate cancer (PCa) is a most common malignancy in the genitourinary system, which imposes a huge burden on the patients and society. Various traditional medication methods fail to achieve satisfactory effects, and therefore it is imperative to develop innovative and effective routes of administration. Drug delivery systems have the characteristics of both delivery and controlled release and are widely used clinically. Prostate-specific membrane antigen (PSMA) is one of the most characteristic and highly selective biomarkers of PCa with a good PCa-targetability. Many drug delivery systems targeting PSMA have been explored, including drug-ligand conjugates and nano-drug delivery systems (polymer nanoparticles, inorganic nanoparticles, liposomes, and biological nanoparticles, etc.). This article reviews the recent studies on the role of the PSMA-targeting drug delivery system in PCa, in order to provide some reference for the precise and effective treatment of the malignancy.
Keywords: prostate cancer; drug delivery system; prostate-specific membrane antigen; targeting.